Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Merck, known as MSD outside the US and Canada, got approval for Vaxneuvance from the FDA in July – a month after Pfizer upped the ante in the competitive stakes with a green light for Prevnar-20 ...